Shihua Yang

Dr. Shihua Yang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Journal of Controlled Release
Verified
Journal Article
Open access
NMNingye Ma
Ningye Ma
JGJian Gao
Jian Gao
XPXiaoao Pang
Xiaoao Pang
KWKexin Wu
Kexin Wu
SYShihua Yang
Shihua Yang
YHYing-Ying Hao
Ying-Ying Hao
Cancer is a major global public health challenge. Traditional treatments such as surgery, radiotherapy, and chemotherapy often show limited efficacy, minimal improvements in survival rates, and high recurrence risks. With limited therapeutic options for solid tumors, tumor immunotherapy, which harness the body's immune system, has gained significant attention. Oncolytic viruses (OVs) selectively infect and destroy tumor cells, induce immunogenic cell death (ICD) and stimulate antitumor immune responses. However, current OVs therapies, which are predominantly administered via intratumoral injection, have numerous limitations, including the need for guidance, suboptimal viral spread, extracellular matrix barriers, and immune clearance. These challenges hinder repeated dosing effectiveness and restrict its clinical applicability. Although genetic engineering has improved the tumor selectivity and immune activation of OVs, significant delivery challenges remain. Recently, optimizing pharmaceutical formulations to enhance tumor targeting and viral accumulation has emerged as a key approach to improving OV therapy and expanding clinical applicability. This review highlights the critical role of pharmaceutical formulations in biologics and outlines recent advances in OVs formulations. Specifically, we discuss strategies aimed at enhancing tumor targeting, reducing adverse effects, and promoting antitumor immunity. These strategies significantly enhance OV therapeutic potential and inform novel delivery systems for clinical translation.

9 September 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZLZifan Li
Zifan Li
SYShihua Yang
Shihua Yang
LSLi-da Su
Li-da Su
The development of drug delivery systems for the treatment of intracranial central nervous system (CNS) diseases remains one of the most intractable medical problems in modern society, owing to the special physiological structure of the brain, including the existence of the blood-brain barrier (BBB), the CNS’s immune privilege, and its high complexity and vulnerability. Recently, a leading approach in the CNS drug delivery domain has been to employ or simulate the physiological behavior of microorganisms to overcome the BBB and remodel the pathological immune microenvironment in intracranial tissue. Considering the exceptional advancements in microorganism-based CNS drug delivery systems, it is imperative to review the latest breakthroughs. Herein, we summarize the emerging trends at the intersection of microorganism-based drug delivery systems and emerging biomedical technology for the treatment of CNS diseases, with a particular focus on preclinical research into microorganism-based drug delivery systems to combat CNS diseases, aiming to describe a credible landscape for further clinical trials.

21 July 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YHYunsa Huo
Yunsa Huo
PYPeng Yu
Peng Yu
TWTianye Wang
Tianye Wang
SYShihua Yang
Shihua Yang
PHPeng Han
Peng Han
ZLZifan Li
Zifan Li
Albumin-bound paclitaxel (Abraxane) exhibits potent antitumor activity, but its suboptimal pharmacokinetics and the restrictive blood-brain barrier (BBB) greatly limit the broader application of albumin-based paclitaxel formulations in intracranial tumors. In this work, we engineered size-uniform (~ 160 nm) paclitaxel-albumin nanoparticles (Fe3+@SA-PTX) via simple one-step nano-precipitation method guided by a “protein corona intervention” strategy. During nanoparticle fabrication, tannic acid-Fe3+ (TA-Fe3+) were strategically introduced. On the one hand, the introduction of TA-Fe3+ shell could slow down the leakage of paclitaxel and improving the stability and pharmacokinetic profile of the nanoparticles. On the other hand, the presence of Fe3+ enabled the nanoparticles to interact with unsaturated transferrin in plasma, forming a stable transferrin protein corona. This endowed the nanoparticles with enhanced tumor-targeting capability and the ability to penetrate the BBB. The Fe3+@SA-PTX exhibited superior pharmacokinetics and therapeutic efficacy against intracranial tumors via intravenous administration.